Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Total Operating Expenses

Total Operating Expenses at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
$159.55M+40.2%
Vera Therapeutics logo
Vera TherapeuticsVERA
$125.13M+119%
PVL
Palvella TherapeuticsPVLA
$14.86M+88.7%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$15.55M+8.0%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$62.67M+20.7%

Segments

By segment

See full
Reportable Segment$126.44M+18.5%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Research and development (1)71,57786,626149,208163,461
Selling, general and administrative54,97520,21693,65437,319
Total operating expenses126,552106,842242,862200,780
Loss from operations(126,268)(106,767)(242,437)(200,633)
Other income (expense), net:
Interest income8,4906,54616,36214,086
Interest expense(8,307)(514)(11,769)(1,100)

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s total operating expenses?
Viridian Therapeutics, Inc. (VRDN) reported total operating expenses of $126.55M in Q2 2026.
How has Viridian Therapeutics, Inc.'s total operating expenses changed year-over-year?
Viridian Therapeutics, Inc.'s total operating expenses increased by 18.4% year-over-year, from $106.84M to $126.55M.
What is the long-term trend for Viridian Therapeutics, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s total operating expenses has grown at a 51.4% compound annual growth rate (CAGR), from $82.69M to $434.24M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Viridian Therapeutics, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude